{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:17:06Z","timestamp":1789877826000,"version":"4.0.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Hemispherx Biopharma"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.vaccine.2014.07.078","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T21:31:48Z","timestamp":1407965508000},"page":"5490-5495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans"],"prefix":"10.1016","volume":"32","author":[{"given":"Edgar Turner","family":"Overton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Strayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.07.078_bib0005","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.07.078_bib0010","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.4049\/jimmunol.178.8.5200","article-title":"TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), Poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules","volume":"178","author":"Gowen","year":"2007","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.vaccine.2014.07.078_bib0015","doi-asserted-by":"crossref","first-page":"12273","DOI":"10.1128\/JVI.79.19.12273-12279.2005","article-title":"Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells","volume":"79","author":"Hewson","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.07.078_bib0020","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.micinf.2007.06.007","article-title":"Intranasal immunization with H5N1 vaccine plus Poly I: Poly C12U, a toll-like receptor agonist, protects mice against homologous and heterologous virus challenge","volume":"9","author":"Ichinohe","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2014.07.078_bib0025","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/jmv.21824","article-title":"Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus","volume":"82","author":"Ichinohe","year":"2010","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2014.07.078_bib0030","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1086\/521304","article-title":"Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine","volume":"196","author":"Ichinohe","year":"2007","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.078_bib0035","doi-asserted-by":"crossref","first-page":"e31334","DOI":"10.1371\/journal.pone.0031334","article-title":"A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome","volume":"7","author":"Strayer","year":"2012","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2014.07.078_bib0040","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1073\/pnas.0711976105","article-title":"The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine","volume":"105","author":"Trumpfheller","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.078_bib0045","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jmv.22273","article-title":"Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine","volume":"84","author":"Ainai","year":"2012","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.078_bib0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1084\/jem.161.1.198","article-title":"Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG","volume":"161","author":"Taylor","year":"1985","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.078_bib0055","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.4049\/jimmunol.160.3.1219","article-title":"In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA","volume":"160","author":"Renegar","year":"1998","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2014.07.078_bib0060","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0264-410X(90)90250-P","article-title":"Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza","volume":"8","author":"Tamura","year":"1990","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.078_bib0065","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/eji.1830210602","article-title":"Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules","volume":"21","author":"Tamura","year":"1991","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.078_bib0070","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/eji.1830220228","article-title":"Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine","volume":"22","author":"Tamura","year":"1992","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2014.07.078_bib0075","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jmv.20173","article-title":"IgA antibodies provide cross-protection against infection with different strains of influenza B virus","volume":"74","author":"Asahi-Ozaki","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2014.07.078_bib0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.282.2.137","article-title":"Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial","volume":"281","author":"Nichol","year":"1999","journal-title":"J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.078_bib0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/infdis\/jis641","article-title":"Localized mucosal response to intranasal live attenuated influenza vaccine in adults","volume":"207","author":"Barria","year":"2012","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.078_bib0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1750-2659.2008.00056.x","article-title":"Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza","volume":"2","author":"Ambrose","year":"2008","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2014.07.078_bib0095","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/315323","article-title":"Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine","volume":"181","author":"Belshe","year":"2000","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T22:54:00Z","timestamp":1689461640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14010457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":19,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0264410X14010457"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.078","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}